Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Not Confirmed
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
01-02 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Industry Trade Show
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
01-02 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025
19 May 2025
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/viiv-healthcare-retakes-1st-place-pharma-reputation-ranking-among-us-patient-groups
13 Mar 2025
// PRESS RELEASE
https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2025/march/investigational-broadly-neutralising-antibody/
12 Mar 2025
// BUSINESSWIRE
24 Jan 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-for-generic-hiv-drug/articleshow/117517932.cms
11 Nov 2024
// BUSINESSWIRE
07 Nov 2024
// BUSINESSWIRE
Details:
VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.
Lead Product(s): VH109,Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: VH3810109
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2025
Lead Product(s) : VH109,Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV’s N6LS Antibody Maintains Long-Acting Viral Suppression in HIV Treatment
Details : VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.
Product Name : VH3810109
Product Type : Antibody
Upfront Cash : Inapplicable
March 12, 2025
Details:
Vocabria (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in combnation with rilpivirine for adolescents' PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vocabria
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces CHMP Positive Opinion for Vocabria + Rekambys HIV Treatment
Details : Vocabria (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in combnation with rilpivirine for adolescents' PrEP to reduce risk of sexually acquired HIV-1 infection.
Product Name : Vocabria
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Details:
Dovato combines the IST inhibitor, dolutegravir with the NRT inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for 12 and older living with HIV.
Lead Product(s): Dolutegravir Sodium,Lamivudine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Dovato
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Fundación Huésped
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 11, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces Dovato is Effective in Treatment-Naïve HIV
Details : Dovato combines the IST inhibitor, dolutegravir with the NRT inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for 12 and older living with HIV.
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2024
Details:
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 01, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Grants Priority Review for ViiV's Cabotegravir for HIV Prevention
Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Product Name : Apretude
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2024
Details:
Dovato (dolutegravir and lamivudine) is the first oral two-drug single-tablet regimen for people aged 12 and older living with HIV.
Lead Product(s): Dolutegravir Sodium,Lamivudine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Dovato
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces FDA Approval Of Dovato for Adolescents with HIV
Details : Dovato (dolutegravir and lamivudine) is the first oral two-drug single-tablet regimen for people aged 12 and older living with HIV.
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Details:
Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Reports Superior Efficacy Of Cabenuva Injectable HIV Treatment
Details : Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.
Product Name : Cabenuva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2024
Details:
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Announces Health Canada Approval for APRETUDE for HIV Pre-Exposure Prophylaxis
Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Product Name : Apretude
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2024
Details:
The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UK MHRA Approves ViiV’s Cabotegravir Formulations for Preventing HIV-1 Infection
Details : The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.
Product Name : Apretude
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2024
Details:
Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Presents Phase I Findings of Cabotegravir Long-acting Injectable for HIV Prevention
Details : Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Product Name : Apretude
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2024
Details:
Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LATITUDE Phase III Data Shows Cabenuva Superior to Daily Therapy for HIV
Details : Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.
Product Name : Cabenuva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2024
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Drinking Solution
Brand Name : Ziagen
Dosage Strength : 20mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Dosage Form : Tabl
Brand Name : Ziagen
Dosage Strength : 300mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Australia
Dosage Form : oral
Brand Name : Ziagen
Dosage Strength : 20 mg/mL
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : tablet
Brand Name : Ziagen
Dosage Strength : 300 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Italy
Dosage Form : Abacavir 300Mg 60 Units ...
Brand Name : Ziagen
Dosage Strength : 60 cpr riv div 300 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Dosage Form : Antic-calc Tablet, Film ...
Brand Name : Ziagen
Dosage Strength : 300 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Dosage Form : Abacavir 20Mg/Ml 240Ml O...
Brand Name : Ziagen
Dosage Strength : os soluz bottle 240 ml...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Canada
Dosage Form : TABLET
Brand Name : TRIUMEQ
Dosage Strength : 600MG
Packaging : 30
Approval Date :
Application Number : 2430932
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Dosage Form : SOLUTION
Brand Name : ZIAGEN
Dosage Strength : 20MG/ML
Packaging : 240 ML
Approval Date :
Application Number : 2240358
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Dosage Form : TABLET
Brand Name : KIVEXA
Dosage Strength : 600MG
Packaging : 30
Approval Date :
Application Number : 2269341
Regulatory Info :
Registration Country : Canada
ABOUT THIS PAGE